In contrast, the tumor-infiltrating lymphocytes (TLSs), CD8+ T lymphocytes, play a pivotal role in survival prognosis, tumor regression, and antitumor immunity, through weakening CD8+ T cell activation, immunosuppressive factors in TME maintain tumor immune inhibition status (37–39). The gene discussed is CD8A; the disease is neoplasm.